CLEAN VERSION OF ENTIRE SET OF PENDING CLAIMS

39. An immunogenic composition comprising a lipooligosaccharide (LOS) isolated from *Moraxella catarrhalis* and detoxified by treating to remove esterified fatty acids to produce detoxified LOS (dLOS) and an immunogenic carrier covalently linked thereto.

40. The immunogenic composition of Claim 39, wherein the immunogenic carrier is a protein.

41. The immunogenic composition of Claim 40, wherein the immunogenic carrier protein is selected from the group consisting of UspA isolated from *M. catarrhalis*, CD isolated from *M. catarrhalis*, tetanus toxin/toxoid, a high molecular weight protein (HMP) isolated from nontypeable *Haemophilus influenzae*, diphtheria toxin/toxoid, detoxified *P. aeruginosa* toxin A, cholera toxin/toxoid, pertussis toxin/toxoid, *Clostridium perfringens* exotoxins/toxoid, hepatitis B surface antigen, hepatitis B core antigen, rotavirus VP 7 protein, CRM, CRM_{197}, CRM_{3201} and respiratory syncytial virus F and G protein.

42. The immunogenic composition of Claim 41, wherein the immunogenic carrier protein is tetanus toxoid or HMP.

43. The immunogenic composition of Claim 39, further comprising an adjuvant.

44. The immunogenic composition of Claim 43, wherein the adjuvant is an admixture of monophosphoryl lipid A and trehalose dimycolate or alum.

45. The immunogenic composition of Claim 39, wherein the immunogenic carrier is covalently linked to dLOS via a linker compound.

46. The immunogenic composition of Claim 45, wherein the linker compound is selected from the group consisting of adipic acid dihydrazide, ε-aminohexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone and p-nitrophenylethyl amine.

47. The immunogenic composition of Claim 45, wherein the linker compound is adipic acid dihydrazide.